Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

912results about How to "High viscoelasticity" patented technology

Compound foaming agent for foam concrete and preparation method thereof

InactiveCN102887663AFine foamCoagulation-promotingFoam concreteFoaming agent
The invention belongs to the technical field of building materials, and specifically relates to a compound foaming agent for a foam concrete and the preparation method of the compound foaming agent. The compound foaming agent is composed of a surfactant, a protein foaming agent, a foam stabilizing agent, a coagulation accelerator and a water reducing agent. The compound foaming agent provided by the invention is doped with few protein foaming agent and foam stabilizing agent in a surfactant solution to remarkably improve the foaming capability and the foam stabilizing time of the surfactant solution and create favorable conditions for preparing the foam concrete at a low-density grade (not more than 500 Kg/m<3>). In addition, the coagulation accelerator is doped to accelerate the condensation of cement slurry and effectively prevent collapsing; the water reducing agent is doped to improve the working property of a freshly mixed concrete, and reduce the water dosage and improve the strength of the foam concrete at the same time. The product provided by the invention has various functions, and is not limited to only prepare the foam; at the same time, the product provided by the invention has the actions of accelerating coagulation and reducing water, and the product provided by the invention is suitable for preparing the low-density foam concrete.
Owner:TONGJI UNIV

Methods, compositions, formulations, and uses of cellulose and acrylic-based polymers

Compositions, formulations, and methods for the treatment or prevention, or decreasing the frequency of transmission of a virus (such as human immunodeficiency virus type 1 (HIV-1), Herpes Simplex virus type 1 (HSV1), or Herpes Simplex Virus Type 2 (HSV2), or other virus), or a bacterial infection (such as Trichomonas vaginalis, Neisseris gonorrhoeae Haemopholus ducreyl, or Chlamydia trachomatis, or other bacterial species), or a fungal infection, using an anionic cellulose- or acrylic-based oligomer, polymer, or copolymer. The present invention also includes administering a therapeutically effective amount of said oligomer, polymer, or copolymer, or a pharmaceutically acceptable salt thereof, or with a pharmaceutically acceptable carrier or diluent, thereof. The invention relies on the unique biochemical substitution of the cellulose or acrylic backbone such that the resultant molecule can remain molecularly dispersed in solution (or gel or other formulation) and mostly dissociated over a wide range of physiological microenvironments, such as the low pH found within the vaginal lumen, preferably from a pH of 14 to below 3.5. These specific substitutions also impart on the resultant molecule potent antiviral, anti-bacterial, and anti-fungal properties. In addition, these compositions can be used as general disinfectants for human use such as in contact lens solutions, mouthwashes, toothpastes, suppositories, or as more generalized disinfectants found in soaps, household cleaning products, paints, water treatments modalities, or can be incorporated into cosmetic, and can be used as vehicles for drug delivery, an adjuvant in a therapeutic formulation, or as a preservative. These compounds can be delivered in a liquid or solid dosage form and can be incorporated into barrier devices such as condoms, diaphragms, or cervical caps, to help prevent the transmission of STDs. The compounds of this invention can also be used in combination therapies with other classes of antiviral, antibacterial, or antifungal agent having similar or differing mechanisms of action including, but not limited to, anionic or cationic polymers, copolymers, or oligomers, surfactants, protease inhibitors, DNA or RNA polymerase inhibitors (including reverse transcriptase inhibitors), fusion inhibitors, cell wall biosynthesis inhibitors, integrase inhibitors, or virus or bacterial attachment inhibitors.
Owner:NOVAFLUX INC +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products